{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:02:47Z","timestamp":1773154967339,"version":"3.50.1"},"reference-count":119,"publisher":"Frontline Medical Communications, Inc.","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.sder.2010.02.002","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T13:17:13Z","timestamp":1272460633000},"page":"35-47","source":"Crossref","is-referenced-by-count":30,"title":["Safety and Efficacy of the Tumor Necrosis Factor Antagonists"],"prefix":"10.12788","volume":"29","author":[{"given":"F.","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sterry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","reference":[{"key":"10.1016\/j.sder.2010.02.002_bib1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","article-title":"Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis","volume":"160","author":"Reich","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.sder.2010.02.002_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","article-title":"Biology of tumor necrosis factor-alpha-implications for psoriasis","volume":"13","author":"Schottelius","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib4","first-page":"303","article-title":"Targeted treatment of psoriasis with adalimumab: A critical appraisal based on a systematic review of the literature","volume":"3","author":"Schmitt","year":"2009","journal-title":"Biologics"},{"issue":"suppl 2","key":"10.1016\/j.sder.2010.02.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.sder.2010.02.002_bib6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09546630601121060","article-title":"Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a phase II randomized controlled trial","volume":"18","author":"Shikiar","year":"2007","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.sder.2010.02.002_bib10","first-page":"50","article-title":"Clinical meaning of change in dermatology life quality index scores","volume":"147","author":"Khilji","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib12","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib13","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.2006.02581.x","article-title":"Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis","volume":"62","author":"Nestorov","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.sder.2010.02.002_bib15","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib16","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.02.002_bib17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib19","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension","volume":"159","author":"van de Kerkhof","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.002_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/205873920601900123","article-title":"Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: Results of a pilot experience (power study)","volume":"19","author":"Cassano","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.sder.2010.02.002_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2133.2006.07585.x","article-title":"Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis","volume":"156","author":"Elewski","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1468-3083.2009.03321.x","article-title":"Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study","volume":"23","author":"Dauden","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.sder.2010.02.002_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.002_bib25","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.02.002_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.sder.2010.02.002_bib28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2133.2008.08728.x","article-title":"Review and expert opinion on prevention and treatment of infliximab-related infusion reactions","volume":"159","author":"Lecluse","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib32","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib34","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","article-title":"Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: A randomized controlled trial","volume":"154","author":"Reich","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib35","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the Infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib37","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib38","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0091270009339192","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis","volume":"49","author":"Xu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.sder.2010.02.002_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","article-title":"Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy","volume":"57","author":"Jiaravuthisan","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/BOR.0b013e3282f4b392","article-title":"The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis","volume":"20","author":"Askling","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib41","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib43","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial","volume":"50","author":"St. Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib44","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.sder.2010.02.002_bib45","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib46","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib47","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor Necrosis Factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib48","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.sder.2010.02.002_bib49","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib50","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib51","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/ard.2006.062760","article-title":"Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists","volume":"66","author":"Askling","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib52","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following Anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib53","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study","volume":"34","author":"den Broeder","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib54","first-page":"653","article-title":"Elective orthopedic surgery and perioperative DMARD management: Many questions, fewer answers, and some opinions","volume":"34","author":"Bongartz","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib55","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (go-after study): A multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.002_bib56","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib57","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The go-FORWARD study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib58","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib59","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib60","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/art.11151","article-title":"Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-gamma production and toll-like receptor 4 expression","volume":"48","author":"Netea","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib61","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumoniae in patients receiving tumor necrosis factor-alpha antagonists","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib62","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","article-title":"Infections associated with tumor necrosis factor-alpha antagonists","volume":"25","author":"Rychly","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.sder.2010.02.002_bib63","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.02.002_bib64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0889-857X(02)00101-1","article-title":"Infection complications associated with the use of biologic agents","volume":"29","author":"Bresnihan","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.sder.2010.02.002_bib65","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib66","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and Anti-tumor Necrosis Factor alpha therapy","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib67","first-page":"40","article-title":"Differences between Anti-tumor Necrosis Factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment","volume":"74","author":"Dinarello","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.sder.2010.02.002_bib68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/ajrccm\/141.2.347","article-title":"Extrapulmonary tuberculosis in the United States","volume":"141","author":"Rieder","year":"1990","journal-title":"Am Rev Respir Dis"},{"issue":"suppl 2","key":"10.1016\/j.sder.2010.02.002_bib69","doi-asserted-by":"crossref","first-page":"ii34","DOI":"10.1136\/ard.62.suppl_2.ii34","article-title":"Advances in targeted therapy: Safety of biological agents","volume":"62","author":"Keystone","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib70","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2000.00898.x","article-title":"Psoriasis, its treatment, and cancer in a cohort of Finnish patients","volume":"114","author":"Hannuksela-Svahn","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib72","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0140-6736(01)06179-7","article-title":"Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: Nested cohort crossover study","volume":"358","author":"Marcil","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.sder.2010.02.002_bib73","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","article-title":"Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study","volume":"120","author":"Paul","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib75","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2133.2008.08669.x","article-title":"Etanercept combined with methotrexate for high-need psoriasis","volume":"159","author":"Driessen","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2340\/00015555-0511","article-title":"The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"suppl 1","key":"10.1016\/j.sder.2010.02.002_bib77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","article-title":"Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles","volume":"34","author":"Anderson","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.02.002_bib79","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clindermatol.2007.10.030","article-title":"Tumor necrosis factor antagonists in the therapy of psoriasis","volume":"26","author":"Mossner","year":"2008","journal-title":"Clin Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.sder.2010.02.002_bib82","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jaad.2005.10.053","article-title":"Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database","volume":"54","author":"Gottlieb","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib83","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/ar1851","article-title":"Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study","volume":"8","author":"Atzeni","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.sder.2010.02.002_bib84","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1191\/0961203305lu2240rr","article-title":"The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: Biological and clinical implications","volume":"14","author":"de Rycke","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.sder.2010.02.002_bib85","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey","volume":"7","author":"de Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"suppl 2","key":"10.1016\/j.sder.2010.02.002_bib86","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jaad.2005.11.1088","article-title":"Efficacy of etanercept in an integrated multistudy database of patients with psoriasis","volume":"54","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib87","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1503\/cmaj.1041597","article-title":"Infliximab and serious hematologic events","volume":"171","author":"Phelan","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.sder.2010.02.002_bib88","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s10067-006-0415-y","article-title":"Antitumor necrosis factor-induced neutropenia: A case report with double positive rechallenges","volume":"26","author":"Montane","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib89","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.02.002_bib90","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.sder.2010.02.002_bib91","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.sder.2010.02.002_bib92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(03)00010-8","article-title":"Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy","volume":"210","author":"Chin","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.sder.2010.02.002_bib93","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2004.00710.x","article-title":"Tumour necrosis factor inhibitors: Risks and benefits in patients with rheumatoid arthritis","volume":"34","author":"Roberts","year":"2004","journal-title":"Int Med J"},{"key":"10.1016\/j.sder.2010.02.002_bib94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000111030","article-title":"Pregnancy and breastfeeding in patients with Crohn's disease","volume":"76","author":"Mottet","year":"2007","journal-title":"Digestion"},{"key":"10.1016\/j.sder.2010.02.002_bib95","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0002-9270(01)03714-5","article-title":"Successful treatment of pregnancy-triggered Crohn's disease complicated by severe recurrent life-threatening gastrointestinal bleeding","volume":"96","author":"James","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib96","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0002-9270(02)05276-0","article-title":"Unexpected dramatic clinical response of psoriasis lesions and unexpected pregnancy in an infertile patient in response to treatment with anti-tumor necrosis factor (TNFalpha) monoclonal antibody for Crohn's disease","volume":"97","author":"Bank","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib97","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1440-1746.2003.02983.x","article-title":"Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody)","volume":"18","author":"Burt","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.sder.2010.02.002_bib98","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s10620-006-9452-2","article-title":"The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy","volume":"51","author":"Coburn","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.sder.2010.02.002_bib99","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00054725-200608000-00020","article-title":"Successful use of adalimumab (Humira) for Crohn's disease in pregnancy","volume":"12","author":"Mishkin","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib100","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/gut.2005.065417","article-title":"Adalimumab use in pregnancy","volume":"54","author":"Vesga","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.sder.2010.02.002_bib101","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1034\/j.1600-0897.2001.d01-25.x","article-title":"Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: A recombinant fusion anti-cytokine treatment for rheumatoid arthritis","volume":"46","author":"Sills","year":"2001","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.sder.2010.02.002_bib102","first-page":"491","article-title":"Etanercept and pregnancy [in Spanish]","volume":"30","author":"Otermin","year":"2007","journal-title":"An Sist Sanit Navar"},{"key":"10.1016\/j.sder.2010.02.002_bib103","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/keh264","article-title":"Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate","volume":"43","author":"Kinder","year":"2004","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.sder.2010.02.002_bib104","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/j.1572-0241.2001.03987.x","article-title":"Infliximab treatment and pregnancy outcome in active Crohn's disease","volume":"96","author":"Srinivasan","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib105","first-page":"1014","article-title":"Tumor necrosis factor-alpha inhibition and VATER Association: A causal relationship","volume":"33","author":"Carter","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib106","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.dld.2006.01.017","article-title":"Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease","volume":"38","author":"Tursi","year":"2006","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.sder.2010.02.002_bib107","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.sder.2010.02.002_bib108","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/rheumatology\/kem068","article-title":"Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy","volume":"46","author":"Rosner","year":"2007","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.sder.2010.02.002_bib109","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1016\/S0016-5085(03)80034-3","article-title":"Outcome of pregnancy in patients receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"124","author":"Katz","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.sder.2010.02.002_bib110","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib111","first-page":"A54","article-title":"Safety of infliximab in Crohn's disease: Data from the 5,000-patient TREAT registry","volume":"126","author":"Lichtenstein","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.sder.2010.02.002_bib112","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/art.22028","article-title":"Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register","volume":"54","author":"Hyrich","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sder.2010.02.002_bib113","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.14309\/00000434-200609001-01073","article-title":"Adalimumab and pregnancy outcome: The Otis autoimmune diseases in pregnancy project","volume":"101","author":"Chambers","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib114","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: A review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J Rheumatol"},{"issue":"suppl 1","key":"10.1016\/j.sder.2010.02.002_bib115","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1136\/gut.2005.081950c","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: Special situations","volume":"55","author":"Caprilli","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.sder.2010.02.002_bib116","first-page":"258","article-title":"Infliximab levels in breast-milk of a nursing Crohn's patient","volume":"96","author":"Peltier","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib117","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3748\/wjg.14.3085","article-title":"Is infliximab safe to use while breastfeeding?","volume":"14","author":"Stengel","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0b013e31817f9367","article-title":"Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery","volume":"43","author":"Kane","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.sder.2010.02.002_bib119","first-page":"1017","article-title":"Etanercept in breast milk","volume":"31","author":"Ostensen","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.sder.2010.02.002_bib120","unstructured":"Gisbert JP: Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis, in press"},{"key":"10.1016\/j.sder.2010.02.002_bib121","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: A review of the literature","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.sder.2010.02.002_bib122","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimes for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.sder.2010.02.002_bib123","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparision of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Eng J Med"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562910000131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562910000131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/01\/Vol29_i1-Safety-and-Efficacy-of-TNF-Antag.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:55:59Z","timestamp":1740038159000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/buy_now\/?id=216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1085562910000131"],"URL":"https:\/\/doi.org\/10.1016\/j.sder.2010.02.002","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}